Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
Status:
Completed
Trial end date:
2020-06-28
Target enrollment:
Participant gender:
Summary
This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the
treatment of ocular Graft Verses Host Disease (oGVHD). Two thirds of participants will
receive Brimonidine and one third will receive ophthalmic buffered saline (placebo).